Company intelligence / Profile preview

Kexing Biopharm Co., Ltd.

Shenzhen, Guangdong, Chinakexingbiopharm.com ↗

Ownership: Private
Development stage: Commercial

Overview

The company has several approved products in China including recombinant human growth hormone, recombinant human interleukin-2, and recombinant human interferon alpha-1b. Recent developments include FDA and NMPA approval for clinical trials of GB05 (Human Interferon α1b Inhalation Solution) for RSV infections, GB08 (long-acting growth hormone) for growth hormone deficiency, and GB18 (nanobody-Fc fusion) for cancer cachexia.

Therapeutic areas: OncologyEndocrinologyInfectious Diseases
Modalities: Recombinant proteinsNanobody-Fc fusion proteinsHormonesInterferonsInterleukinsBiological products
Industry: Biotech

Drug pipeline

4 assets

GB27

Preclinical

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Kexing Biopharm Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kexing Biopharm Co., Ltd..

Explore the full profile